Thomas J Murdock

US Patent:

6650934, Nov 18, 2003

Filed:

Nov 7, 1997

Appl. No.:

08/966437

Inventors:

Thomas O. Murdock - Vadnais Heights MN 55127

International Classification:

A61N 130

US Classification:

604 20, 604 22, 264494, 424449, 521141

Abstract:

A method is provided for preparing a novel therapeutic agent-containing reservoir ( ) for use in conjunction with an electrotransport drug delivery system ( ). A polymeric matrix is foamed in a selected atmosphere and then cross-linked to form a polymeric closed-cell foam matrix reservoir ( ). The method enables relatively smaller quantities of therapeutic agent to be loaded into the electrotransport system ( ) and is especially useful for the transdermal delivery of more costly drugs, such as peptides and proteins produced from genetically engineered cell lines, and/or highly potent drugs for which a small dosage is efficacious. Reservoirs ( ) prepared according to this method and electrotransport devices ( ) containing such reservoirs are also provided.

US Patent:

62469045, Jun 12, 2001

Filed:

Nov 7, 1997

Appl. No.:

8/965881

Inventors:

Thomas O. Murdock - Vadnais Heights MN

Assignee:

ALZA Corporation - Mountain View CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

A novel electrotransport drug delivery system (10) and therapeutic agent-containing reservoir (26, 28) for use therein are provided. An inert filler material effective to reduce the quantity of therapeutic agent otherwise present is incorporated in the reservoir (26, 28) along with the therapeutic agent to be delivered via electrotransport. Methods for making the reservoir (26, 28) and drug delivery system (10) are provided as well.

US Patent:

51380161, Aug 11, 1992

Filed:

Dec 18, 1990

Appl. No.:

7/629242

Inventors:

Thomas O. Murdock - Vadnais Heights MN
Brian W. Carlson - Woodbury MN

Assignee:

H. B. Fuller Company - Saint Paul MN

International Classification:

C08G 1822

US Classification:

528 55

Abstract:

Significant improvements in the utility of oxazolidone and polyoxazolidone compounds and in their manufacture can be achieved using a novel catalyst in the reaction between a hindered isocyanate and an epoxy, forming oxazolidone ring structures. The novel catalyst of the invention promotes the efficient and rapid formation of oxazolidone and polyoxazolidone compounds. The use of hindered isocyanate in the reaction prevents formation of side reaction products such as isocyanate trimer, allophanate and biuret.

US Patent:

60399775, Mar 21, 2000

Filed:

Dec 9, 1997

Appl. No.:

8/987372

Inventors:

Subramanian S. Venkatraman - Palo Alto CA
Thomas O. Murdock - Vadnais Heights MN
Stephanus Pudjijanto - San Jose CA

Assignee:

Alza Corporation - Palo Alto CA

International Classification:

A61K 910
A61K 4732
A61M 3700

US Classification:

424486

Abstract:

Pharmaceutical hydrogel formulations containing polyvinyl alcohol are provided. The formulations may serve as rug reservoirs in electrotransport drug delivery systems or passive transdermal systems, or they may be used in a variety of other types of dosage forms, e. g. , capsules, suppositories, aerosols, and the like. With these formulations, there is virtually no syneresis encountered upon long term storage, an advantage that derives from selecting the quantity of polyvinyl alcohol in the gel to correspond to the polymer's degree of hydrolysis.

US Patent:

48267198, May 2, 1989

Filed:

Jul 15, 1986

Appl. No.:

6/885933

Inventors:

Thomas O. Murdock - Vadnais Heights MN
Paul L. Krankkala - Woodbury MN

Assignee:

H. B. Fuller Company - St. Paul MN

International Classification:

B05D 124
B32B 700

US Classification:

428182

Abstract:

Corrugating adhesive free of incompatibility problems with a fully hydrolyzed polyvinyl alcohol comprise a major portion of water, starch, strong base, a boric acid compound and a fully hydrolyzed water soluble polyvinyl alcohol composition.

US Patent:

60715081, Jun 6, 2000

Filed:

Dec 18, 1997

Appl. No.:

8/993213

Inventors:

Thomas Owen Murdock - Vadnais Heights MN

Assignee:

Alza Corporation - Mountain View CA

International Classification:

A61K 31785
A61K 3174
A61F 1300

US Classification:

424 7812

Abstract:

A method is provided for preparing drug formulations suitable for electrotransport drug delivery. The drug to be delivered, present in salt form, is contacted with an ion exchange material prior to incorporation into the reservoir (26) of an electrotransport delivery system (10). In this way, the drug salt is partially or completely neutralized. This technique is useful for adjusting the pH of the drug formulation without incorporating extraneous materials, e. g. , competing ions or the like, into the reservoir (26).

US Patent:

60045779, Dec 21, 1999

Filed:

Aug 12, 1997

Appl. No.:

8/909678

Inventors:

Thomas O. Murdock - Vadnais Heights MN

International Classification:

A61K 970

US Classification:

424443

Abstract:

Improved electrotransport of therapeutic agents which include agent cations and polybasic anionic counterions. Improved electrotransport is obtained by treating the therapeutic agent with a multivalent metal compound of the formula MX where M is a metallic cation having a valency of at least +2 and is reactive with the polybasic anionic counter ion and X is a pH-increasing anion. Reduction in species which compete with the therapeutic agent for electrotranport is obtained.

US Patent:

61819638, Jan 30, 2001

Filed:

Nov 2, 1999

Appl. No.:

9/433615

Inventors:

Ivan W. Chin - Belmont CA
Thomas O. Murdock - Vadnais Heights MN

Assignee:

Alza Corporation - Mountain View CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. The cathode includes a cathodic electrode and a cathodic reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes i) a drug or an electrolyte salt or a mixture thereof and ii) a cetylpyridinium salt in an amount sufficient to inhibit microbial growth in the aqueous medium. The polymeric material is compatible with the cetylpyridinium salt. A process is also provided wherein when electric current flows from the source of electrical power so that the drug is transdermally delivered to the patient by electrotransport from the anodic reservoir, the cetylpyridinium salt is not transdermally delivered to the patient by electrotransport from the cathodic reservoir. A process for preparing a transdermal electrotransport drug delivery device is also provided.

Address:

4582 S Jupiter Dr, Salt Lake City, UT 84124

VIN:

1GCHK23KX7F560122

Make:

CHEVROLET

Model:

SILVERADO 2500HD

Year:

2007

Address:

1762 N 700 W, Mapleton, UT 84664

Phone:

(801)4891192

VIN:

2G4WD582471205672

Make:

BUICK

Model:

LACROSSE

Year:

2007